藥品供應與健保藥價調整制度之謅議【本期企劃】 試閱
Discussion on Drug Supply and Drug Price Adjustment System of Health Insurance
藥品為商品，其價值來自治療疾病的效果，其價格與品質必是連動的。邇來社會熱議健保調降藥價致用藥短缺問題，本文由法制面探究藥事及健保法規其管制目的，觀察執行落差，認為健保總額藥品支出目標制僅是缺藥原因之一，而市場有限，廠商以藥價差競爭，一旦價格與製造成本失序，影響製造品質管理，恐為缺藥之主因。故健保署宜明訂價差管理，食藥署以劑型及產能為主疏導製藥產業，並以必要藥品為核心，二署充分合作，建立供需平臺，融入供應鏈，重建核價機制，留備安全產能，爰作成政策及法規執行建議，提供醫藥法政界參考。
Treating diseases are value of drugs, and its price and quality must be linked. This paper explores the regulations of pharmaceutical affairs and health insurance, observes the implementation drop, and believes that DET is only one of the reasons for drug shortage, and the market is limited, and manufacturers compete with price gap, and quality reduced, are the main reason. Therefore, it is recommended to clearly set the management of price gaps, establish a necessary drug supply and demand platform, rebuild the price adjustment mechanism, reserve safe production capacity, and make suggestions provide references.
023-041
